1. Median event-free survival was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant). 2. Grade...

1. Local progression-free survival at 3 years was 84.3% in the SBRT group vs 67.3% in the RFA group, with...

1. Median progression-free survival was 9.4 months in the imlunestrant–abemaciclib group vs 5.5 months in the imlunestrant group with HR...

1. The complete response rate at the overall phase in cycle 1 was 77.7% vs 78.2% with treatment vs control...

1. Progression-free survival at 12 months was 79% with nivolumab/ipilimumab vs 21% with chemotherapy, and 24-month PFS was 72% and...

1. Median PFS was 6.6 months in the switch maintenance group and 3.5 months in the control group with HR...

1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the cetuximab group with HR 1.33...

1. The median progression-free survival was 15.0 months in the inavolisib and 7.3 months in the placebo group, with HR...

1. Progression-free survival had a hazard ratio of 0.38 (extrapancreatic NETs) and 0.23 (pancreatic NETs) for those treated with cabozantinib...

1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse...